Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 182-193 http://medscipublisher.com/index.php/cge 190 more precisely to cancer cells, thereby reducing exposure to non-target cells, is also a critical area of research (Mainini and Eccles, 2020; Chen et al., 2021). 7.3 Future research directions Future research in RNAi therapy for cervical cancer should focus on several key areas. First, the development of more efficient and targeted delivery systems remains a priority. This includes exploring new nanomaterials and ligand-based targeting strategies to improve the specificity and efficacy of siRNA delivery (Chen et al., 2018; Mainini and Eccles, 2020; Gangopadhyay et al., 2021). Second, comprehensive studies are needed to better understand the mechanisms of off-target effects and to develop strategies to mitigate these risks (Pai et al., 2006; Miele et al., 2012). Third, combining RNAi therapy with other treatment modalities, such as chemotherapy, radiotherapy, and immunotherapy, could enhance therapeutic outcomes and overcome resistance mechanisms (Chen et al., 2021; Tian et al., 2021). Finally, advancing RNAi therapy from preclinical models to clinical trials will require rigorous evaluation of safety, efficacy, and long-term effects in patients (Pai et al., 2006; Takeshita and Ochiya, 2006). 8 Concluding Remarks RNA interference (RNAi) has emerged as a revolutionary tool in the field of cancer therapy, particularly for cervical cancer. The mechanism of RNAi, which involves sequence-specific gene silencing, offers a targeted approach to inhibit the expression of oncogenes such as E6 and E7 in human papillomavirus (HPV)-induced cervical cancer. The application of RNAi in cancer therapy has shown promising results in preclinical models, demonstrating significant antiproliferative and proapoptotic effects. Despite the challenges associated with in vivo delivery and potential off-target effects, RNAi-based therapies are advancing towards clinical trials, highlighting their potential as a novel therapeutic strategy. The long-term outlook for RNAi in cervical cancer therapy is optimistic but requires overcoming several hurdles. The development of safe and effective delivery systems remains a critical challenge. Current strategies, including lipid-based delivery systems and exosomes, have shown promise in improving the cellular affinity and reducing the immunogenicity of RNAi therapeutics. Additionally, the selection of appropriate gene targets and the design of RNAi molecules to minimize off-target effects are essential for the success of these therapies. As research progresses, it is anticipated that RNAi will become an integral part of personalized cancer therapy, offering tailored treatments based on the genetic profile of individual tumors. In conclusion, RNAi represents a groundbreaking advancement in the treatment of cervical cancer, providing a highly specific and efficient method for gene silencing. The potential of RNAi to target and silence oncogenes specific to cancer cells offers a promising avenue for developing more effective and less toxic cancer therapies. While significant progress has been made, continued research and development are necessary to address the current limitations and fully harness the therapeutic potential of RNAi. The future of RNAi in cancer therapy looks promising, with the potential to significantly improve patient outcomes and revolutionize the approach to cancer treatment. Acknowledgments Thank you to the anonymous peer reviewers for providing constructive suggestions for revisions to this manuscript. Conflict of Interest Disclosure The authors affirm that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Agrawal N., Dasaradhi P., Mohmmed A., Malhotra P., Bhatnagar R., and Mukherjee S.., 2003, RNA interference: biology, mechanism, and applications, Microbiology and Molecular Biology Reviews, 67(4): 657-685. https://doi.org/10.1128/MMBR.67.4.657-685.2003 Almeida A., Queiroz J., Sousa F., and Sousa Â., 2019, Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins, Drug Discovery Today, 24(10): 2044-2057. https://doi.org/10.1016/j.drudis.2019.07.011
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==